{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T04:29:15Z","timestamp":1785644955206,"version":"3.56.0"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T00:00:00Z","timestamp":1716595200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>In 2014 the incidence of anti-3-hydroxy-3-methylglutaryl-CoA-reductase (HMGCR) myopathy in New Zealand was \u223c1.7 case\/million persons\/year. This study aimed to re-estimate the population incidence and assess ethnic variation in those aged &amp;gt;40\u2009years old.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>An incidence cohort was defined by seropositivity for immunoprecipitating anti-HMGCR autoantibodies tested at a national reference laboratory between 1 October 2019 and 30 September 2021. Separately, ethnicity standardized incidence in &amp;gt;40\u2009year olds discharged from New Zealand public hospitals for idiopathic and unspecified myopathy [International Statistical Classification of Disease and Related Health Problems Tenth Revision Australian Modification (ICD-10 AM) codes M60.8\/M60.9], was examined for concordance.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The 40 patients identified in the incidence cohort were all &amp;gt;40\u2009years old and all had a prior history of statin use. Annual incidence was 4 cases\/million\/year (95% CI 2.8\u20135.5). In those &amp;gt;40\u2009years old the incidence in Polynesians (M\u0101ori and Pacific Peoples combined) was 25 cases\/million\/year (95% CI 15.9\u201340.1), in Asians 5.7 cases\/million\/year (95% CI 0.7\u201320.5) and in Europeans 7 cases\/million\/year (95% CI 3.1\u20138.4). The risk in statin users aged &amp;gt;40\u2009years was \u223c1\/9000 in Polynesians and \u223c1\/48\u200a000 in Europeans. Ethnic difference in incidence of idiopathic and unspecified myopathy (ICD AM codes M60.8\/M60.9) was also found in hospital discharges.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>In the past half decade the estimated incidence of anti-HMGCR myopathy in New Zealand has doubled. Polynesian peoples of New Zealand &amp;gt;40\u2009years old have an estimated 5-fold higher risk compared with European and Asian peoples. The estimated absolute risk in statin users &amp;gt;40\u2009years old was 108 cases\/million\/year in Polynesians vs 21 cases\/million\/year in Europeans.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keae282","type":"journal-article","created":{"date-parts":[[2024,5,26]],"date-time":"2024-05-26T03:28:05Z","timestamp":1716694085000},"page":"1362-1368","source":"Crossref","is-referenced-by-count":7,"title":["Anti-HMGCR myopathy: estimated five-fold higher incidence in Polynesian compared with European populations in Aotearoa\/New Zealand"],"prefix":"10.1093","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4589-0735","authenticated-orcid":false,"given":"Ke Li","family":"Chow","sequence":"first","affiliation":[{"name":"Department of Immunology, Canterbury Health Laboratories , Christchurch,","place":["New Zealand"]},{"name":"Department of Immunology, NSW Health Pathology , Newcastle, NSW,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula Elizabeth","family":"Keating","sequence":"additional","affiliation":[{"name":"Department of Immunology, Canterbury Health Laboratories , Christchurch,","place":["New Zealand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John Liston","family":"O\u2019Donnell","sequence":"additional","affiliation":[{"name":"Department of Immunology, Canterbury Health Laboratories , Christchurch,","place":["New Zealand"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,5,25]]},"reference":[{"key":"2025030500185812300_keae282-B1","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.nmd.2006.10.007","article-title":"Progressive myopathy with up-regulation of MHC-1 associated with statin therapy","volume":"17","author":"Needham","year":"2007","journal-title":"Neuromuscul Disord"},{"key":"2025030500185812300_keae282-B2","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.jsps.2023.04.002","article-title":"Statins utilization trends and expenditure in the U.S. before and after the implementation of the 2013 ACC\/AHA guidelines","volume":"31","author":"Matyori","year":"2023","journal-title":"Saudi Pharm J"},{"key":"2025030500185812300_keae282-B3","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1002\/art.27572","article-title":"A novel autoantibody recognizing 200 kd and 100 kd proteins is associated with immune mediated necrotising myopathy","volume":"62","author":"Christopher-Stine","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2025030500185812300_keae282-B4","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/art.30156","article-title":"Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy","volume":"63","author":"Mammen","year":"2011","journal-title":"Arthritis Rheum"},{"key":"2025030500185812300_keae282-B5","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1002\/acr.21671","article-title":"Increased frequency of DRB111:01 in anti-HMG-CoA reductase-associated autoimmune myopathy","volume":"64","author":"Mammen","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025030500185812300_keae282-B6","first-page":"D783","article-title":"Allele frequency net database (AFND) 2020 update: gold-standard data classification, open access genotype data and new query tools","volume":"48","author":"Gonzalez-Galarza","year":"2020","journal-title":"Nucleic Acid Research"},{"key":"2025030500185812300_keae282-B7","doi-asserted-by":"crossref","first-page":"103468","DOI":"10.1016\/j.autrev.2023.103468","article-title":"Anti-HMGCR immune mediated necrotising myopathy: addressing the remaining issues","volume":"22","author":"Khoo","year":"2023","journal-title":"Autoimmunity Rev"},{"key":"2025030500185812300_keae282-B8","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/s41584-023-01033-0","article-title":"Epidemiology of the idiopathic inflammatory myopathies","volume":"19","author":"Khoo","year":"2023","journal-title":"Nat Review Rheumatol"},{"key":"2025030500185812300_keae282-B9","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/imj.13023","article-title":"HMGCR-associated myositis: a New Zealand case series and estimate of incidence","volume":"46","author":"Kennedy","year":"2016","journal-title":"Intern Med J"},{"key":"2025030500185812300_keae282-B10","first-page":"508","article-title":"Performance of the EULAR\/ACT classification criteria for inflammatory myopathies in patients with myositis-specific autoantibodies","volume":"74","author":"Casal-Dominguez","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"2025030500185812300_keae282-B11","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.cca.2017.07.011","article-title":"Detection of autoantibodies to 3\u2014hydroxy-3-methglutaryl-coenzyme a reductase by ELISA in a reference laboratory setting","volume":"472","author":"Jaskowski","year":"2017","journal-title":"Clinica Chimica Acta"},{"key":"2025030500185812300_keae282-B12","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41584-024-01106-8","article-title":"Reply to: current classification criteria underestimate the incidence of idiopathic inflammatory myopathies by ignoring subgroups","volume":"20","author":"Khoo","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"2025030500185812300_keae282-B13","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/s41584-024-01105-9","article-title":"Current classification criteria underestimate the incidence of idiopathic inflammatory myopathies by ignoring subgroups","volume":"20","author":"Giannini","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"2025030500185812300_keae282-B14","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1002\/art.40320","article-title":"2017 European League against Rheumatism\/American College of Rheumatology Classification criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and their Major Subgroups","volume":"69","author":"Lundberg","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2025030500185812300_keae282-B15"},{"key":"2025030500185812300_keae282-B16"},{"key":"2025030500185812300_keae282-B17"},{"key":"2025030500185812300_keae282-B18","year":"2016"},{"key":"2025030500185812300_keae282-B19","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1073\/pnas.1015876108","article-title":"High-precision radiocarbon precision dating shows recent and rapid initial human colonisation of East Polynesia","volume":"108","author":"Wilmshurst","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"2025030500185812300_keae282-B20","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1001\/jamacardio.2016.4700","article-title":"National trends in statin use and expenditures in the US adult population from 2002 to 2013: insights from the medical expenditure panel survey","volume":"2","author":"Salami","year":"2017","journal-title":"JAMA Cardiol"},{"key":"2025030500185812300_keae282-B21","doi-asserted-by":"crossref","first-page":"e018524","DOI":"10.1136\/bmjopen-2017-018524","article-title":"Cross-sectional analysis of the prevalence and predictors of statin utilisation in Ireland with a focus on primary prevention of cardiovascular disease","volume":"8","author":"Byrne","year":"2018","journal-title":"BMJ Open"},{"key":"2025030500185812300_keae282-B22","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1007\/s00228-022-03343-w","article-title":"Prevalence and initiation of statin therapy in the oldest old- a longitudinal population-based study","volume":"78","author":"Sundvall","year":"2022","journal-title":"European J Clin Pharm"},{"key":"2025030500185812300_keae282-B23","first-page":"14","article-title":"Ethnic difference in cardiovascular risk profiles among 475,241 adults in primary care in Aotearoa","volume":"133","author":"Selak","year":"2020","journal-title":"New Zealand. N Z Med J"},{"key":"2025030500185812300_keae282-B24","first-page":"54","article-title":"Lipid monitoring in a community cohort of people taking statins: who is tested and is testing associated with subsequent alteration in therapy","volume":"133","author":"Beadel","year":"2020","journal-title":"N Z Med J"},{"key":"2025030500185812300_keae282-B25","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1093\/rheumatology\/kev229","article-title":"Increasing incidence of immune-mediated necrotising myopathy: single centre experience","volume":"54","author":"Klein","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"2025030500185812300_keae282-B26","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1161\/01.cir.0000437741.48606.98","article-title":"2013 ACC\/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"129","author":"Goff","year":"2014","journal-title":"Circulation"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keae282\/57985909\/keae282.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/3\/1362\/57985909\/keae282.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/3\/1362\/57985909\/keae282.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:22:24Z","timestamp":1741134144000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/64\/3\/1362\/7682384"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,25]]},"references-count":26,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,5,25]]},"published-print":{"date-parts":[[2025,3,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keae282","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2024,5,25]]}}}